GALT Valuation

Galectin Therapeutics Inc

Add to Watchlist

Advanced Chart

4.700

-0.07(-1.468%)1D

Overview
Forecast
Valuation
Earnings

GALT Relative Valuation

GALT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GALT is overvalued; if below, it's undervalued.

Historical Valuation

Galectin Therapeutics Inc (GALT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.21. The fair price of Galectin Therapeutics Inc (GALT) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：4.70

Fair

-10.19

Trailing

Forward

0.00

EV/EBITDA

Galectin Therapeutics Inc. (GALT) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-15.58

EV/EBIT

Galectin Therapeutics Inc. (GALT) has a current EV/EBIT of -15.58. The 5-year average EV/EBIT is -3.72. The thresholds are as follows: Strongly Undervalued below -8.64, Undervalued between -8.64 and -6.18, Fairly Valued between -1.27 and -6.18, Overvalued between -1.27 and 1.19, and Strongly Overvalued above 1.19. The current Forward EV/EBIT of -15.58 falls within the Strongly Undervalued range.

0.00

Galectin Therapeutics Inc. (GALT) has a current PS of 0.00. The 5-year average PS is 1.04. The thresholds are as follows: Strongly Undervalued below -8.15, Undervalued between -8.15 and -3.55, Fairly Valued between 5.64 and -3.55, Overvalued between 5.64 and 10.24, and Strongly Overvalued above 10.24. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Galectin Therapeutics Inc. (GALT) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.09. The thresholds are as follows: Strongly Undervalued below -4.87, Undervalued between -4.87 and -2.98, Fairly Valued between 0.81 and -2.98, Overvalued between 0.81 and 2.70, and Strongly Overvalued above 2.70. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Galectin Therapeutics Inc. (GALT) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.59. The thresholds are as follows: Strongly Undervalued below -3.25, Undervalued between -3.25 and -1.92, Fairly Valued between 0.73 and -1.92, Overvalued between 0.73 and 2.06, and Strongly Overvalued above 2.06. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Galectin Therapeutics Inc (GALT) has a current Price-to-Book (P/B) ratio of -2.54. Compared to its 3-year average P/B ratio of -2.00 , the current P/B ratio is approximately 27.21% higher. Relative to its 5-year average P/B ratio of 16.66, the current P/B ratio is about -115.27% higher. Galectin Therapeutics Inc (GALT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -30.50%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -25.58% , the current FCF yield is about -100.00% lower.

-2.54

P/B

Median3y

-2.00

Median5y

16.66

-11.66

FCF Yield

Median3y

-30.50

Median5y

-25.58

Competitors Valuation Multiple

The average P/S ratio for GALT's competitors is 0.00, providing a benchmark for relative valuation. Galectin Therapeutics Inc Corp (GALT) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

GALT.O

Galectin Therapeutics Inc

Voyager Therapeutics Inc

Cartesian Therapeutics Inc

Foghorn Therapeutics Inc

Allogene Therapeutics Inc

Loss

321.53M

Performance Decomposition

Market capitalization of GALT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of GALT in the past 1 year is driven by Unknown.